Literature DB >> 11121146

Mutant loricrin is not crosslinked into the cornified cell envelope but is translocated into the nucleus in loricrin keratoderma.

A Ishida-Yamamoto1, H Kato, H Kiyama, D K Armstrong, C S Munro, R A Eady, S Nakamura, M Kinouchi, H Takahashi, H Iizuka.   

Abstract

Loricrin is a major constituent of the epidermal cornified cell envelope. We have recently identified heterozygous loricrin gene mutations in two dominantly inherited skin diseases, the ichthyotic variant of Vohwinkel syndrome and progressive symmetric erythrokeratoderma, collectively termed loricrin keratoderma. In order to see whether the mutant loricrin molecules predicted by DNA sequencing are expressed in vivo and to define their pathologic effects, we raised antibodies against synthetic peptides corresponding to the mutated sequences of loricrin. Immunoblotting of horny cell extracts from loricrin keratoderma patients showed specific bands for mutant loricrin. Immunohistochemistry of loricrin keratoderma skin biopsies showed positive immunoreactivity to the mutant loricrin antibodies in the nuclei of differentiated epidermal keratinocytes. The immunostaining was localized to the nucleoli of the lower granular cell layer. As keratinocyte differentiation progressed the immunoreactivity moved gradually into the nucleoplasm leaving nucleoli mostly nonimmunoreactive. No substantial staining was observed along the cornified cell envelope. This study confirmed that mutant loricrin was expressed in the loricrin keratoderma skin. Mutant loricrin, as a dominant negative disrupter, is not likely to affect cornified cell envelope crosslinking directly, but seems to interfere with nuclear/nucleolar functions of differentiating keratinocytes. In addition, detection of the mutant loricrin in scraped horny layer could provide a simple noninvasive screening test for loricrin keratoderma. J Invest Dermatol 115:1088-1094 2000

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11121146     DOI: 10.1046/j.1523-1747.2000.00163.x

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  8 in total

1.  Activation of vascular endothelial growth factor receptor 2 in a cellular model of loricrin keratoderma.

Authors:  Kozo Yoneda; Toshio Demitsu; Kozo Nakai; Tetsuya Moriue; Wataru Ogawa; Junsuke Igarashi; Hiroaki Kosaka; Yasuo Kubota
Journal:  J Biol Chem       Date:  2010-03-17       Impact factor: 5.157

2.  TRPV3 mutants causing Olmsted Syndrome induce impaired cell adhesion and nonfunctional lysosomes.

Authors:  Manoj Yadav; Chandan Goswami
Journal:  Channels (Austin)       Date:  2016-10-18       Impact factor: 2.581

3.  Suppressing AP1 factor signaling in the suprabasal epidermis produces a keratoderma phenotype.

Authors:  Ellen A Rorke; Gautam Adhikary; Christina A Young; Dennis R Roop; Richard L Eckert
Journal:  J Invest Dermatol       Date:  2014-08-22       Impact factor: 8.551

4.  A novel microdeletion in LOR causing autosomal dominant loricrin keratoderma.

Authors:  V A Kinsler; S Drury; A Khan; R Waelchli; G Rukaite; A Barnicoat; N Lench; J I Harper; R F L O'Shaughnessy
Journal:  Br J Dermatol       Date:  2014-12-09       Impact factor: 9.302

Review 5.  Loricrin - an overview.

Authors:  S Nithya; T Radhika; Nadeem Jeddy
Journal:  J Oral Maxillofac Pathol       Date:  2015 Jan-Apr

6.  Novel autosomal dominant mutation in loricrin presenting as prominent ichthyosis.

Authors:  E Pohler; F Cunningham; A Sandilands; C Cole; S Digby; J R McMillan; S Aristodemou; J A McGrath; F J D Smith; W H I McLean; C S Munro; M Zamiri
Journal:  Br J Dermatol       Date:  2015-08-22       Impact factor: 9.302

7.  Loricrin and NRF2 Coordinate Cornification.

Authors:  Yosuke Ishitsuka; Tatsuya Ogawa; Yoshiyuki Nakamura; Noriko Kubota; Yasuhiro Fujisawa; Rei Watanabe; Naoko Okiyama; Manabu Fujimoto; Dennis R Roop; Akemi Ishida-Yamamoto
Journal:  JID Innov       Date:  2021-10-15

8.  Progressive symmetrical erythrokeratodermia -- case report.

Authors:  Bianca de Mello Guaraldi; Thaís Jerez Jaime; Rafael de Mello Guaraldi; Daniel Fernandes Melo; Osvania Maris Nogueira; Nilton Rodrigues
Journal:  An Bras Dermatol       Date:  2013 Jan-Feb       Impact factor: 1.896

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.